Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PRMTs and Arginine Methylation: Cancer's Best-Kept Secret?

Literature DB >> 31230909

PRMTs and Arginine Methylation: Cancer's Best-Kept Secret?

Abstract

Post-translational modification (PTM) of proteins is vital for increasing proteome diversity and maintaining cellular homeostasis. If the writing, reading, and removal of modifications are not controlled, cancer can develop. Arginine methylation is an understudied modification that is increasingly associated with cancer progression. Consequently protein arginine methyltransferases (PRMTs), the writers of arginine methylation, have rapidly gained interest as novel drug targets. However, for clinical success a deep mechanistic understanding of the biology of PRMTs is required. In this review we focus on advances made regarding the role of PRMTs in stem cell biology, epigenetics, splicing, immune surveillance and the DNA damage response, and highlight the rapid rise of specific inhibitors that are now in clinical trials for cancer therapy. Crown

Entities: Chemical Disease

Keywords: DNA repair; PRMT; arginine methylation; cancer; cancer stem cells; epigenetic

Mesh：

Substances：

Year: 2019 PMID： 31230909 DOI： 10.1016/j.molmed.2019.05.007

Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 11.951

Keyword Cloud
Cited

66 in total

Review 1. Protein arginine methylation: from enigmatic functions to therapeutic targeting.

Authors: Qin Wu; Matthieu Schapira; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy
Journal: Nat Rev Drug Discov Date: 2021-03-19 Impact factor: 84.694

2. Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands.

Authors: Marthe Solleder; Philippe Guillaume; Julien Racle; Justine Michaux; Hui-Song Pak; Markus Müller; George Coukos; Michal Bassani-Sternberg; David Gfeller
Journal: Mol Cell Proteomics Date: 2019-12-17 Impact factor: 5.911

Review 3. Protein arginine methyltransferase 5: a potential cancer therapeutic target.

Authors: Yuanyang Yuan; Hong Nie
Journal: Cell Oncol (Dordr) Date: 2021-01-19 Impact factor: 6.730

4. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As₂O₃ by stabilizing oncoprotein PML-RARα.

Authors: Xinping Huang; Yongfeng Yang; Dan Zhu; Yan Zhao; Min Wei; Ke Li; Hong-Hu Zhu; Xiaofeng Zheng
Journal: Cell Mol Life Sci Date: 2022-05-27 Impact factor: 9.261

5. Genetic evidence for partial redundancy between the arginine methyltransferases CARM1 and PRMT6.

Authors: Donghang Cheng; Guozhen Gao; Alessandra Di Lorenzo; Sandrine Jayne; Michael O Hottiger; Stephane Richard; Mark T Bedford
Journal: J Biol Chem Date: 2020-10-02 Impact factor: 5.157

Review 6. Non-Histone Arginine Methylation by Protein Arginine Methyltransferases.

Authors: Ayad A Al-Hamashi; Krystal Diaz; Rong Huang
Journal: Curr Protein Pept Sci Date: 2020 Impact factor: 3.272

7. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells.

Authors: Tianzhi Huang; Yongyong Yang; Xiao Song; Xuechao Wan; Bingli Wu; Namratha Sastry; Craig M Horbinski; Chang Zeng; Deanna Tiek; Anshika Goenka; Fabao Liu; Cameron W Brennan; John A Kessler; Roger Stupp; Ichiro Nakano; Erik P Sulman; Ryo Nishikawa; Charles David James; Wei Zhang; Wei Xu; Bo Hu; Shi-Yuan Cheng
Journal: Mol Cell Date: 2021-02-03 Impact factor: 17.970

PRMTs and Arginine Methylation: Cancer's Best-Kept Secret?

Review 1. Protein arginine methylation: from enigmatic functions to therapeutic targeting.

2. Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands.

Review 3. Protein arginine methyltransferase 5: a potential cancer therapeutic target.

4. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As₂O₃ by stabilizing oncoprotein PML-RARα.

5. Genetic evidence for partial redundancy between the arginine methyltransferases CARM1 and PRMT6.

Review 6. Non-Histone Arginine Methylation by Protein Arginine Methyltransferases.

7. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells.

8. Arginine methylation: the promise of a 'silver bullet' for brain tumours?

Review 9. Protein arginine methyltransferases: promising targets for cancer therapy.

Review 10. Using Chemical Epigenetics to Target Cancer.

PRMTs and Arginine Methylation: Cancer's Best-Kept Secret?

Review 1. Protein arginine methylation: from enigmatic functions to therapeutic targeting.

2. Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands.

Review 3. Protein arginine methyltransferase 5: a potential cancer therapeutic target.

4. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RARα.

5. Genetic evidence for partial redundancy between the arginine methyltransferases CARM1 and PRMT6.

Review 6. Non-Histone Arginine Methylation by Protein Arginine Methyltransferases.

7. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells.

8. Arginine methylation: the promise of a 'silver bullet' for brain tumours?

Review 9. Protein arginine methyltransferases: promising targets for cancer therapy.

Review 10. Using Chemical Epigenetics to Target Cancer.

4. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As₂O₃ by stabilizing oncoprotein PML-RARα.